The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.

Genor Biopharma, a China-based immuno-oncology therapy developer backed by poultry feed producer Charoen Pokphand, has filed to raise up to HK$2.48bn ($320m) in an initial public offering, DealStreetAsia reported yesterday. Founded in 2007, Genor is developing monoclonal antibodies to treat cancers including solid tumours and blood cancers, in addition to autoimmune diseases such as rheumatoid…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.